June 29, 2017 10:14 AM EDT
News Briefing

As­traZeneca and Chi­na part­ner Chi-Med launch a glob­al PhI­II; Zai Lab bags $30M for R&D ef­fort

Shehla Shakoor

Managing Director

→ Un­der­scor­ing a com­mit­ment to de­vel­op­ing can­cer drugs for a world mar­ket, Chi­na’s Chi-Med and its part­ners at As­traZeneca have start­ed a Phase III …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times